Mylan recalls 10mg Prasugrel tablets that failed 18-month stability testing. These tablets may not be safe for long-term use. Consumers should contact Mylan for details.
“Mylan Prasugrel Tablets Recall: Failed Stability Testing Risk.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/1004698-mylan-prasugrel-tablets-recall-failed-stability-testing-risk. Based on FDA recall #D-0839-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0839-2026%22&limit=1).
The FDA announced on August 17, 2026, that Mylan Pharmaceuticals Inc. is recalling Prasugrel Tablets, USP, 10mg due to failed dissolution specifications. The agency classified the recall as Class II.
How to tell if you have it
Brand: Mylan
Product: Prasugrel Tablets, USP, 10mg, Rx only, 30 Tablets in each bottle
NDC: 0378-5186-93
Lot #: 3225272
Expiration Date: September 30, 2026
Quantity: 47,662 bottles
The hazard
The product failed to meet 18-month stability testing acceptance criteria. The FDA stated the hazard is failed dissolution specifications.
Context
GovInfoNow's records show Mylan Pharmaceuticals Inc. has 54 other recalls on record since June 28, 2012. Other recent recalls of similar products include Mylan Mycophenolate Mofetil Injections (August 26, 2026), Mylan Acamprosate Tablets (July 24, 2026), and Mylan Mycophenolate Mofetil Injection (July 2, 2026). Other recent recalls of similar products include Apotex Paxil CR 37.5mg Tablets (August 13, 2026), Golden State Medical Prasugrel HCl 10mg Tablets (August 21, 2026), and Cipla Phytonadione Injectable Emulsion (October 31, 2025).
How to tell if you have this one
Check for the lot number 3225272 on the bottle. The product was made in India and expires September 30, 2026.
Brand
Mylan
Category
Drug
Based on the official FDA remedy
What to do — step by step
Contact Mylan
Reach out to Mylan Pharmaceuticals for specific instructions on what to do with the recalled tablets.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide within the U.S” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 23 days after the firm started it.
1Firm started the recall
2Published in FDA’s Enforcement Report
3FDA classified it Class II
4Added to GovInfoNow
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0839-2026 (August 17, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0839-2026 to see it in context.
Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.